Ayuda
Ir al contenido

Dialnet


An Update on Anti-TNF Agents in Ulcerative Colitis

  • Autores: Mark A. Samaan, Preet Bagi, Niels Vande Casteele, Geert R. D'Haens, Barrett G. Levesque
  • Localización: Gastroenterology clinics of North America, ISSN 0889-8553, Vol. 43, Nº. 3, 2014 (Ejemplar dedicado a: Biologics in Inflammatory Bowel Disease), págs. 479-494
  • Idioma: inglés
  • Enlaces
  • Resumen
    • Anti-tumor necrosis factor-α agents are key therapeutic options for the treatment of ulcerative colitis. Their efficacy and safety have been shown in large randomized controlled trials. The key evidence gained from these trials of infliximab, adalimumab, and golimumab is reviewed along with their effect on mucosal healing and long-term outcomes. Also reviewed are methods for optimizing their effectiveness, including therapeutic drug monitoring and treat-to-target strategies. Finally, remaining unresolved questions regarding their role and effectiveness are considered including how these may be addressed in future clinical trials.


Fundación Dialnet

Dialnet Plus

  • Más información sobre Dialnet Plus

Opciones de compartir

Opciones de entorno